Zoetis (NYSE:ZTS) Given New $180.00 Price Target at Stifel Nicolaus

Zoetis (NYSE:ZTS) had its price objective lowered by analysts at Stifel Nicolaus from $195.00 to $180.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 13.54% from the company’s current price.

A number of other research analysts also recently issued reports on the company. Piper Sandler restated an “overweight” rating and set a $195.00 price target (down previously from $220.00) on shares of Zoetis in a research note on Tuesday, April 16th. Barclays cut their target price on shares of Zoetis from $260.00 to $230.00 and set an “overweight” rating on the stock in a report on Tuesday, April 23rd. StockNews.com cut shares of Zoetis from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 20th. Finally, The Goldman Sachs Group raised their price objective on shares of Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a research report on Wednesday, January 17th. Eight investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $216.13.

Zoetis Stock Down 0.4 %

Shares of NYSE:ZTS opened at $158.53 on Tuesday. The company has a current ratio of 3.36, a quick ratio of 2.00 and a debt-to-equity ratio of 1.32. The firm has a 50 day simple moving average of $170.07 and a 200-day simple moving average of $178.97. The company has a market capitalization of $72.51 billion, a PE ratio of 31.27, a P/E/G ratio of 2.44 and a beta of 0.85. Zoetis has a twelve month low of $144.80 and a twelve month high of $201.92.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Tuesday, February 13th. The company reported $1.24 earnings per share for the quarter, missing analysts’ consensus estimates of $1.32 by ($0.08). The company had revenue of $2.21 billion during the quarter, compared to analysts’ expectations of $2.19 billion. Zoetis had a net margin of 27.43% and a return on equity of 51.25%. Zoetis’s revenue was up 8.5% on a year-over-year basis. During the same period last year, the firm earned $1.15 earnings per share. On average, equities analysts predict that Zoetis will post 5.78 EPS for the current fiscal year.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 923 shares of the stock in a transaction dated Thursday, April 18th. The shares were sold at an average price of $151.17, for a total value of $139,529.91. Following the completion of the transaction, the executive vice president now owns 14,800 shares in the company, valued at approximately $2,237,316. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold a total of 2,209 shares of company stock valued at $371,293 in the last ninety days. 0.16% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Zoetis

Institutional investors have recently modified their holdings of the company. Cary Street Partners Investment Advisory LLC boosted its position in Zoetis by 7.4% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 93,735 shares of the company’s stock worth $16,308,000 after purchasing an additional 6,457 shares in the last quarter. Peak Financial Advisors LLC acquired a new position in shares of Zoetis during the 4th quarter worth $2,776,000. BLB&B Advisors LLC boosted its position in shares of Zoetis by 1.9% in the 3rd quarter. BLB&B Advisors LLC now owns 60,872 shares of the company’s stock worth $10,591,000 after buying an additional 1,107 shares in the last quarter. Ninety One UK Ltd boosted its position in shares of Zoetis by 13.1% in the 4th quarter. Ninety One UK Ltd now owns 108,293 shares of the company’s stock worth $21,374,000 after buying an additional 12,537 shares in the last quarter. Finally, Raymond James Financial Services Advisors Inc. grew its stake in Zoetis by 10.9% in the 4th quarter. Raymond James Financial Services Advisors Inc. now owns 183,564 shares of the company’s stock valued at $36,230,000 after acquiring an additional 17,976 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.